Nonstimulant now first-line option for ADHD


According to the American Academy of Child and Adolescent Psychiatry (AACAP), attention-deficit/hyperactivity disorder (ADHD) affects 3% to 5%of school-age children, and it is estimated that 4% of adults in the U.S. have ADHD. Clinicians that treat those with this disorder can now refer to guidelines that include the only medication indicated specifically for the treatment of this condition in children, adolescents, and adults. AACAP recently issued updated guidelines for managing ADHD and recommended atomoxetine (Strattera, Eli Lilly) as a first-line therapeutic option.

Related Content
© 2024 MJH Life Sciences

All rights reserved.